Research in contextEvidence before this studyHER2 plays critical roles in tumourigenesis and is associated with poor prognosis of breast cancers. Although some tumours respond well to anti-HER2 therapies, many are resistant *de novo* or following therapy. Epigenetic mechanisms influencing HER2-driven cancers and drug resistance are largely unknown.Added value of this studyThis study is novel in revealing a feed forward loop in HER2 signalling and discovering novel epigenetic mechanisms in HER2 gene expression and HER2 signalling in breast cancers. This study screened secretion of cytokines affected by histone demethylase PHF8 in HER2 positive breast cells. The HER2-PHF8-IL-6 regulatory axis verified here contributes to the resistance to Trastuzumab *in vitro* and may play a critical role in the infiltration of T-cells in HER2-driven breast cancers.Implications of all the available evidenceElevated PHF8 in HER2 positive breast cancer may play an important role in the immune response by altering the tumour microenvironment and influencing T cell trafficking to tumour sites by regulating cytokine production. This study gains mechanistic insights into the potential application of PHF8 inhibitors in the resistance of anti-HER2 therapies.Alt-text: Unlabelled box

1. Introduction {#sec0005}
===============

Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death of American women. Thus, approximately 268,600 new cases of breast cancer will be diagnosed, and approximately 41,760 women will die from breast cancer in 2019 in the United States [@bib0001]. Breast cancers include the following (not mutually exclusive) categories: oestrogen receptor (ER)-positive; ERBB2/HER2/NEU (HER2)-positive (HER2+), and triple-negative. HER2+ breast cancers represent 20%--30% of breast cancers and are often associated with poor prognosis [@bib0002]. HER2 is a transmembrane receptor protein tyrosine kinase that plays critical roles in the development of cancer and resistance to therapy of patients with HER2+ \[[@bib0002],[@bib0003]\] and HER2-negative (HER2-) \[[@bib0002],[@bib0003]\] and HER2-negative (HER2-) [@bib0004], [@bib0005], [@bib0006] breast cancers. In the later cases, such as luminal or triple-negative breast cancer, HER2 expression is elevated within a defined group of cancer stem cells that are believed to be the true oncogenic population in the heterogeneous breast cancer and to confer resistance to both hormone and radiation therapies [@bib0004], [@bib0005], [@bib0006]. Trastuzumab, a humanised anti-HER2 antibody, and lapatinib, a HER2 kinase inhibitor, dramatically improve the efficacy of treatment of patients with HER2+ breast cancer or gastric cancer [@bib0007]. Notably, these anti-HER2 therapies achieve beneficial outcomes when administered to HER2+ patients with cancer [@bib0008]. However, drug resistance often develops *de novo*, which hinders therapy [@bib0002]. Thus, to identify novel therapeutic targets that are critical for HER2-driving tumour development and resistance to therapy is still needed.

Investigations of the importance of epigenetic mechanisms in oncogenesis have shifted focus on developing cancer therapeutics that target chromatin regulators \[[@bib0009],[@bib0010]\]. For example, targeting bromodomain and extra terminal domain proteins (BETs) using the inhibitor JQ1 antagonises the proliferation of multiple myeloma cells by repressing MYC and its downstream effectors [@bib0011]. Similarly, targeting the histone demethylase KDM4 family member NCDM-32B effectively inhibits the proliferation and malignant transformation of breast cancer cells [@bib0012]. In the context of HER2, the association of epigenetic changes including DNA methylation, histone modifications, and ncRNAs/miRNAs associated with HER2+ breast cancer susceptibility are the focus of a detailed review [@bib0013]. Importantly, histone deacetylase (HDAC) and DNA methylation inhibitors upregulate *HER2* expression \[[@bib0013],[@bib0014]\]. Moreover, methylation of histone-3 lysine 4 (H3K4me3) and that of histone-3 lysine 9 (H3K9me2) are associated with the induction or downregulation of *HER2* expression, respectively [@bib0013]. Thus, WDR5, a core component of H3K4me3 methyltransferase and G9a, the H3K9me2 methyltransferase, may be responsible for the changes in these modifications [@bib0013]. However, whether and how histone demethylase, another major contributor to epigenetic mechanisms, influences *HER2* expression, and HER2-driven tumour development and resistance to therapy are unknown.

Our team recently reported that histone demethylase PHD finger protein 8 (PHF8) promotes the epithelial-to-mesenchymal transition (EMT) and contributes to breast tumourigenesis [@bib0015]. Further, PHF8 is expressed at relatively higher levels of HER2+ breast cancer cell lines, and PHF8 is required for their anchorage-independent growth. PHF8 demethylates histones H3K9me2 and H3K27me2 [@bib0016], [@bib0017], [@bib0018], [@bib0019] and H4K20me1 \[[@bib0020],[@bib0021]\]. These studies discovered the general transcriptional coactivator function of PHF8. Further, PHF8 is overexpressed and associated with the malignant phenotypes of diverse cancers such as prostate cancer \[[@bib0022],[@bib0023]\], oesophageal squamous cell carcinoma [@bib0024], lung cancer [@bib0025], and hepatocellular carcinoma [@bib0026]. Our team further identified the MYC-miR-22-PHF8 regulatory axis upregulates MYC expression, which in turn indirectly upregulates *PHF8* expression through repression of microRNA-22 (*miR-22*) that represses *PHF8* \[[@bib0015],[@bib0023]\]. Moreover, a USP7-PHF8-positive feedback loop was discovered in which deubiquitinase USP7 stabilises PHF8, and PHF8 transcriptionally upregulates USP7 in breast cancer cells [@bib0027]. Through this mechanism, stabilised PHF8 upregulates *CCNA2* to augment the proliferation of breast cancer cells [@bib0027]. These data support the conclusion that elevated expression of PHF8 contributes to its oncogenic activity. However, the epigenetic regulatory role that PHF8 plays in HER2-driven tumour development and resistance to anti-HER2 therapy is unknown.

We report here that PHF8 expression was elevated in HER2+ breast cancers and in cells that overexpressed HER2. The upregulation of PHF8 played a coactivator role in *HER2* expression and that of genes upregulated by activated HER2 signalling. Moreover, we demonstrate that PHF8 contributed to the upregulation of IL-6 expression *in vitro* and *in vivo* and that the PHF8-IL-6 axis mediated resistance to anti-HER2 drugs. This study illuminates the potential for drug development aimed at inhibiting histone demethylase in HER2-driven tumour development and in the resistance to therapy.

2. Materials and methods {#sec0006}
========================

2.1. Cell lines and treatments {#sec0007}
------------------------------

All cell lines used in this study were obtained from the American Type Culture Collection (Rockville, MD, USA). MCF-7, MDA-MB-231, K562 and HEK293T cells were grown in Dulbecco\'s Modified Eagle Medium (DMEM) containing 10% FBS (Gibco). HCC1954, SKBR3 and BT474 cells were cultured in RPMI1640 medium containing 10% FBS. MCF10A cells were cultured in DMEM-F12 supplemented with 20 ng/ml Epidermal Growth Factor (EGF) (Sigma), 100 ng/ml cholera toxin (Sigma), 10 g/ml insulin (Sigma), 500 ng/ml hydrocortisone (Sigma), and 5% horse serum. All cell lines used in this study were maintained in the specified medium supplemented with 1 × Penicillin--Streptomycin (Gibco) and incubated in 5% CO~2~ at 37 °C. MCF7-HER2, MCF10A-HER2 (overexpressing HER2), PHF8 inducible knocking down SKBR3, BT474 and HCC1954 stable cell lines were obtained as described earlier [@bib0015]. Briefly, cDNA of HER2 were cloned into the *XhoI* and *NotI* sites of the pOZ retroviral vector, PHF8 shRNAs were cloned into the *AgeI* and *EcoRI* sites of a TetON-pLKO-puro lentivirus vector, which was a gift from Dmitri Wiederschain (Addgene plasmid \#21915, RRID:Addgene_98398) [@bib0028]. Retrovirus and lentivirus packaging of the pOZ and TetON-pLKO-puro vectors, infection, and stable selection were performed as described previously [@bib0020]. Briefly, Cells were infected with pOZ virus for 72 h and selected with anti-IL-2α receptor, which was conjugated with magnetic beads. Cell infected with control or PHF8 shRNAs were subjected to puromycin selection. Doxycycline at 1 μg/ml and 0.5 μg/ml was applied to induce the expression of target shRNAs for experiments lasting \< 72 h and 6 days, respectively. Knockdown efficiency was verified by quantitative RT-PCR and western blotting. Two different shRNAs per target gene were tested to reduce off-target effects. PHF8 in house rabbit-anti-PHF8 [@bib0020] for western blotting, HER2 (29D8, RRID:AB_2799587), PARP (46D11, RRID:AB_659884), CDH2 (13A9, RRID:AB_2798427), pAKT (Ser473) (193H12, RRID:AB_331168) from Cell signalling Technology, γ-TUBULIN (MA1-850, RRID:AB_2211249) from Thermo Fisher; TFAP2C (sc-12762, RRID:AB_667770), c-MYC (SC-40, RRID:AB_627268), ZEB1 (sc-10572, RRID:AB_2273177), pSTAT3 (SC-7993, RRID:AB_656682), STAT3 (sc-482, RRID:AB_632440) from Santa Cruz, β-ACTIN (Ab8227, RRID:AB_2305186) were used for western blotting.

T-DM1[@bib0029] (Kadcyla, Genentech) was used to treat cells for 24 h. Dimethyl sulfoxide (equal volume to that of treated cells) was added to the culture media of the control cells. Human Cytokine Antibody Array blots probed with the cell cultured media. Serum free media were added after doxycycline induction for 72 h of each cell line and collected after 24 h culturing. Recombinant human IL-6 was purchased from PeproTech (Rocky Hill, NJ). Enzyme-linked immunosorbent array (ELISA) 10,000 cells were seeded in 6-well plates with complete medium of each cell line with FBS for 24 h. Then the medium was completely replaced to serum-free medium for another 24 h, and the supernatant was tested using the Quantikine human IL-6 (sensitivity \< 5 pg/mL) ELISA kit (R&D Systems, Inc., Minneapolis, MN) according to manufacturer\'s recommended conditions. For some experiments, cells were induced with doxycycline for 72 h first before serum-free medium replacement, and the cytokine in the media was analysed by ELISA.

2.2. RNA-seq analysis {#sec0008}
---------------------

Gene expression analysis by next generation RNA sequencing (RNA-seq) was performed on RNA isolated from overexpression of HER2 MCF10A cells with two PHF8 inducible shRNAs versus double mock vectors control cells, which were marked as mock/ctlshRNA, HER2/ctlshRNA, HER2/PHF8shRNA1 and HER2/PHF8shRNA2 groups. Expression values were calculated as FPKM (fragment per kilobase of exon per million of mapped fragments) and were used to determine differential expression of mRNAs in four groups of samples.

Transcripts were called expressed if FPKM values in overexpression of HER2 with shRNA control samples were ≥1.0 for mRNAs. The mean expression level and differences in expression between four groups were calculated, and from these statistically significant differences in expression between each group was determined using a paired *t*-test. Fold change (HER2/shNC versus mock/shNC) was calculated to identify differentially expressed transcripts. Transcripts were deemed differentially expressed by OE-HER2 if the fold change was ≥1.5 or ≤0.5, with *p* value less than or equal to 0.05. Additionally, transcripts were deemed as PHF8 conserved regulated if mean fold change of HER2/ PHF8shRNA1 or 2 versus HER2/shNC was ≥1.3 or ≤0.7 (*p* ≤ 0.05) and regulation by two shRNAs were of same trend. Differentially expressed mRNAs that significantly regulated by PHF8 are represented by heatmaps by Graphpad prism 7, and Z scores were scaled by row using standard Z score calculation of log 10 absolute FPKM values.

2.3. ChIP and ChIP-qPCR {#sec0009}
-----------------------

Chromatin immunoprecipitations (ChIPs) were performed as described previously [@bib0015]. Briefly, formaldehyde crosslinked cells were lysed and sonicated to shear the DNA. The sonicated DNA--Protein complexes were immunoprecipitated with the following antibodies: control IgG (A01008, RRID:AB_1108307), anti-TFAP2C (sc-12762, RRID:AB_667770), anti-PHF8 (ab36068, RRID:AB_2050177), anti-H3K4me3 (ab8580, RRID:AB_306649), anti-H3K27ac (ab4729, RRID:AB_2118291)). The immuno complexes were collected using protein A/G agarose beads. The eluted DNA and 1% of respective input DNA were reverse cross-linked at 65 °C overnight and used for the qPCR using SYBR Green qPCR mix and a CFX96 instrument (BioRad).

2.4. Cell proliferation assay (MTT) {#sec0010}
-----------------------------------

Cells were seeded at a density of 3 × 10^3^ cells/well in a 96-well plate with outer wells left empty for addition of PBS. After 24 h of culture, the media was changed and vehicle, drugs, or IL-6 (100 ng/mL) [@bib0030] were added. The cells were incubated with inhibitors or drugs for the time specified; then 0.5 mg/mL MTT dye was added and the cells were incubated for an additional 4 hr. Formazan crystals were dissolved in dimethyl sulfoxide (DMSO) for 15 min and the plates were read spectrophotometrically at 590 nm with a reference of 650 nm. Each assay was performed at least three times with five wells replication.

2.5. Mouse works {#sec0011}
----------------

*Phf8* knockout mice were established by Dr. Yang Shi\'s lab at Harvard Medical School. Briefly, the *Phf8^fl^°^x/fl^°^x^* allele was generated by flanking exon 8 with two *loxp* cassettes. Exon 8 of *Phf8* encodes amino acid residues 261--316 of the C-terminal JmjC domain containing a 2-oxoglutarate (2-OG)-binding residue (K264) ([Fig. 5](#fig0005){ref-type="fig"}A). Deletion of this region truncates PHF8 and abolishes its demethylase activity. We used *MMTV-Cre* to knockout *Phf8* (KO) from mammary epithelial cells.

*MMTV-Her2* mice were provided by Dr. Weizhou Zhang. *MMTV-Her2, MMTV-Cre*, and *Phf8^fl^°^x/fl^°*^x^ mice were crossed to generate wild-type (WT) PHF8 mice: *MMTV-Her2/MMTV-Cr*e, *MMTV-Her2/Phf8^fl^°^x/fl^°^x^*, and PHF8 KO mice: *MMTV-Her2/MMTV-Cre/Phf8^fl^°^x/fl^°^x^*. Notably, because *Phf8* resides on the X chromosome, a segment of *MMTV-HER2/MMTV-Cre/Phf8^fl^°^x/wt^* is completely deleted because of inactivation of the X chromosome as shown in [Fig. 5](#fig0005){ref-type="fig"}C. All mice have been fully backcrossed to FVB/N mice (from the Jackson Laboratory) for 8 generations. *Her2-*driven mammary tumours were monitored every 3 days. At experimental endpoint when largest tumour reaches 2 cm in diameter, animals were sacrificed, and all mammary tumours were removed and weighed. After the mice were sacrificed, tumour weight was directly measured, and tumour ratio was calculated as percentage of body weight. Tumours were fixed, embedded in paraffin, and serially sectioned at a thickness of 6--8 μm, and IHC staining was performed as described previously [@bib0015].

2.6. Immunohistochemical staining (IHC) {#sec0012}
---------------------------------------

Histological tissue arrays (BR10010c, BR1503d, BR1504a, BR244 and BR082a) purchased from USBIOMAX were routinely processed as previously described [@bib0015]. Both protease-induced epitope retrieval and heat-induced epitope retrieval were carried out. Endogenous peroxidase activity was blocked with 3% H~2~O~2~. After blocking by reagent (Immunoperoxidase Secondary Detection System, Millipore), immunohistochemical blotting was performed using PHF8 antibody (PHF8 IHC-00343, RRID: AB_1264338) 100x diluted in PBST with 1% goat serum. Biotinylated secondary goat anti-mouse IgG/goat anti-rabbit IgG (Millipore) antibody was used in labelling with IHC Select® Immunoperoxidase Secondary Detection System (Millipore) for PHF8 detection. Pictures were taken by a Nikon digital camera through Nikon Eclipse 80i microscope.

2.7. Ethics statement {#sec0013}
---------------------

The mouse work in this study was conducted according to the procedures approved by the Ethics Committee (the Institutional Animal Care and Use Committee (IACUC)) at The University of Iowa and complied with animal use guidelines. Human tissue microarrays were purchased from USBIOMAX from which the clinical information on patient cohorts for expression analysis is openly available for research use and has been de-identified.

2.8. Statistical analysis {#sec0014}
-------------------------

GraphPad Prism software (v7) was used to conduct statistical analysis. Results are expressed as the mean ± SD. Differences between experimental groups were compared using an unpaired two-tailed Student\'s *t*-test (for two conditions). A \**p* value \<=0.05 was considered statistically significant. \*\* *p* value \<=0.01 was considered highly significant.

2.9. Oligonucleotides {#sec0015}
---------------------

All oligonucleotides were synthesized by IDT and sequence of each was listed below.Oligonucleotides namesSequence*PHF8* RT-qPCR FGCAAACCGCAGCACCACACCT*PHF8* RT-qPCR RCGAGTCTCTGCTTTGCTGTG*HER2* RT-qPCR FTGTGTGGACCTGGATGACAAGG*HER2* RT-qPCR RCTCCGTTTCCTGCAGCAGTCT*IL-6* RT-qPCR FAGCCAGAGCTGTGCAGATGAGTA*IL-6* RT-qPCR RTGACCAGAAGAAGGAATGCCCAT*RPL13A* RT-qPCR FCCTGGAGGAGAAGAGGAAAGAGA*RPL13A* RT-qPCR RTTGAGGACCTCTGTGTATTTGTCAAMouse *Rpl13a* RT-qPCR FGGTGGAAGTACCAGGCAGTGACAMouse *Rpl13a* RT-qPCR RGAGGACCTCTGTGAACTTGCAGATMouse *actinb* RT-qPCR FGGCTGTATTCCCCTCCATCGMouse *actinb* RT-qPCR RCCAGTTGGTAACAATGCCATGTMouse *il-6* RT-qPCR FTCCAGTTGCCTTCTTGGGACMouse *il-6* RT-qPCR RGTACTCCAGAAGACCAGAGGMouse *Phf8* RT-qPCR FTGACTCCAACCCTACCCAAGMouse *Phf8* RT-qPCR RCGGCTGTTCTACCTCCTTCA*IL-6* ChIP-qPCR TSS FACATCCTCGACGGCATCTCA*IL-6 ChIP*-qPCR TSS RGAACCCAGCAAAGACCTCCTA*IL-6 ChIP*-qPCR UTR FAAAGGCTTTGGCCACCAGTA*IL-6 ChIP*-qPCR UTR RCAGGATCAGCACCAAGGGTTHuman *HER2* cDNA *XhoI* FGAC GAC CTC GAG ATG GAG CTG GCG GCCTTG TGC CGC THuman *HER2* cDNA *NotI* RGAC GAC GCG GCC GCC ACT GGC ACG TCC AGACCC AGG TA*HER2* ChIP promoter 1 FCCCTGCTGTGTCCATATATCGAG*HER2* ChIP promoter 1 RGGATAGTTACAGGTACGTTTAGGAA*HER2* ChIP promoter 2 FCGAAGAGAGGGAGAAAGTGAAGCT*HER2* ChIP promoter 2 RGGAATCTCAGCTTCACAACTTCAT*HER2* ChIP CTCF FCCCCGACTTGAGGTATCCTT*HER2* ChIP CTCF RGGGGCATACAAAAGAGGGCT*HER2* ChIP NRE FCCCTCTGACGTCCATCATCTCT*HER2* ChIP NRE RCTCCGTTTCCTGCAGCAGTCT*MMTVHER2*genotyping FTTT CCT GCA GCA GCC TAC GC*MMTVHER2*genotyping RCGG AAC CCA CAT CAG GCC*MMTVCre* genotyping FGCG GTC TGG CAG TAA AAA CTA TC*MMTVCre* genotyping RGTG AAA CAG CAT TGC TGT CAC TT*Flox* genotyping FCAGTAGGTAGCATGGTTTTGTGTGGA*Flox* genotyping RTTCAATAAGAGTATTACCCTATACATTTC

3. Results {#sec0016}
==========

3.1. PHF8 expression is elevated in HER2+ breast cancers and upregulated by HER2 {#sec0017}
--------------------------------------------------------------------------------

Prompted by findings that higher expression of PHF8 in HER2+ breast cancer cells is required for their anchorage-independent growth [@bib0015], we performed Gene Expression Profiling Interactive Analysis [@bib0031] to initially evaluate *PHF8* mRNA levels in breast cancers. Intriguingly, we found that *PHF8* mRNA levels were only slightly elevated amongst breast cancers and their subtypes (*n* = 1085) compared to those of normal tissues (*n* = 291) (Supplementary Figure 1A and 1B). PHF8 is subject to the activities of post-transcriptional and post-translational regulators such as MYC-miR-22-PHF8 \[[@bib0015],[@bib0023]\] and USP7-PHF8 [@bib0027]; consequently, the actual PHF8 protein levels in cancers can differ from those of its mRNA. Therefore, we used immunohistochemistry (IHC) to analyse cancer tissue arrays with 486 breast cancers, 20 normal breast tissues, and 50 metastatic lymph nodes samples (US BIOMAX). Significant increases were detected in PHF8 protein levels (strong nuclear staining) across breast cancers and all subtypes, including HER2+ breast cancers (Supplementary Table 1 and [Fig. 1](#fig0001){ref-type="fig"}A). These data, together with higher PHF8 levels in the HER2+ breast cancer cell lines SKBR3 and BT474 [@bib0015], suggested the regulation of PHF8 by HER2.Fig. 1PHF8 expression is elevated in HER2+ breast cancers and is upregulated by HER2.**a.** Immunohistochemistry (IHC) was used to measure PHF8 levels in breast cancer tissue arrays. Representative PHF8 staining of breast cancer and normal adjacent tissues: Basal like, Luminal A, Luminal B, and HER2+ samples. Magnification: 200 ×, bar = 10 μm. **b.** Western blot and RT-PCR analyses of the levels of PHF8 (upper panel) and its mRNA (lower panel) in MCF10A and MCF7 cells with or without overexpression of HER2. **c**. Western blotting and RT-PCR analyses of *PHF8* protein (upper panel) and mRNA (lower panel) levels in MCF10A-HER2 and MCF7-HER2 cells with or without HER2 knockdown. \* *p* ≤ 0.05; \*\* *p* ≤ 0.01.Fig. 1

Moreover, we found that the overexpression of HER2 in cells infected using the pOZ retroviral system upregulated the levels of PHF8 and its mRNA levels in MCF10A and MCF7 ([Fig. 1](#fig0001){ref-type="fig"}B). Conversely, *HER2* knockdown using siRNAs specific for the *HER2* gene body inhibited the upregulation of PHF8 in these cells but significantly increased *PHF8* mRNA levels in MCF7 cells ([Fig. 1](#fig0001){ref-type="fig"}C). Further, *HER2* knockdown in SKBR3, BT474 and HCC1954 cells downregulated PHF8 levels (Supplementary Figure 2), such decrement on PHF8 levels were also observed by anti-HER2 drugs (Supplementary Figure 2 and Supplementary Figure 8a). Moreover, a significant positive correlation between *HER2* and *PHF8* mRNAs was found through analyses of the databases as follows: Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA), TCGA normal breast tissue, and Genotype-Tissue Expression (GTEx) Program mammary tissue (Supplementary Figure 1C). Together, these findings support the hypothesis that elevated expression of HER2 upregulates that of PHF8.

3.2. PHF8 is a transcriptional coactivator of *HER2* {#sec0018}
----------------------------------------------------

The coactivator role of PHF8 caused us to hypothesise that PHF8 participates in the transcriptional regulation of *HER2*. PHF8 ChIP-seq data acquired from human embryonic H1 cells and K562 cells [@bib0032] indicate enrichment of PHF8 bound to the two promoter regions of *HER2* (Supplementary Figure 3). It is not surprising, therefore, that PHF8 colocalized with H3K4me3, because PHF8 binds to H3K4me3 through its PHD domain [@bib0020]. Importantly, we identified similar enrichment of PHF8 on *HER2* promoters in SKBR3, BT474, and HCC1954 cells ([Fig. 2](#fig0002){ref-type="fig"}A). Loss of function of *PHF8* in cells expressing a *PHF8*-specific siRNA or shRNA in SKBR3, BT474, and HCC1954 cells uniformly downregulated the levels of HER2 and those of its mRNA ([Fig. 2](#fig0002){ref-type="fig"}B), supporting the conclusion that PHF8 functions as a coactivator in the transcriptional regulation of *HER2*. We recently identified a novel HER2 gene body enhancer (HGE), which recruits transcription factor TFAP2C [@bib0033], a positive regulator of *HER2* expression [@bib0034], [@bib0035], [@bib0036], [@bib0037], [@bib0038]. Notably, *TFAP2C* is a direct target of PHF8 [@bib0020]. Thus, when we were searching for if PHF8 regulated *TFAP2C* in HER2+ cells, we found that *PHF8* knockdown downregulated levels of TFAP2C and those of its mRNA ([Figs. 2](#fig0002){ref-type="fig"}B and Supplementary Figure 4). Moreover, the enrichment of TFAP2C at *HER2* promoters was reduced in *PHF8*-RNAi cells ([Fig. 2](#fig0002){ref-type="fig"}C), indicating that the regulation of TFAP2C by PHF8 contributed to *HER2* expression.Fig. 2PHF8 functions as a transcriptional coactivator that regulates HER2 expression. **a.**Chromatin immunoprecipitation (ChIP) analysis of PHF8 bound to *HER2* in HER2+ cells. Enrichment of PHF8 on the *HER2* promoter 1 (P1), promoter 2 (P2), HER2 gene body regulatory element (HGE), and an unmodified region (NC) were analysed using ChIP-qPCR. Relative enrichment represents the average fold-enrichment of PHF8 vs. the input, normalised to the NC region. **b.** Western blotting and RT-PCR analyses of the levels of HER2 and its mRNA in the indicated cells with and without PHF8 knockdown. NC: control scrambled siRNA or shRNA; PHF8-siRNAs, PHF8-si1 and PHF8-si2 and PHF8 shRNAs, PHF8-sh1 and PHF8-sh2, are described in the methods section. Lower panel: RT-qPCR analysis of *HER2* mRNA expression normalised to that of *RPL13A*. **c.** ChIP-qPCR analysis of the recruitment of H3K27ac, H3K4me3, and TFAP2C to *HER2* in HER2+ cells with PHF8 knockdown. The Student *t-*test was performed to evaluate the significance of differences between variables. \* *p* ≤ 0.05, \*\* *p* ≤ 0.01.Fig. 2

*HER2* is constitutively active in HER2+ breast cancer cells, therefore, possesses an active chromatin state. Thus, PHF8 demethylation substrates such as H3K9me2, H4K20me1, and H3K27me2 may not be highly enriched at *HER2* promoters. By contrast, H3K4 me3 is required for the transcriptional regulation of *HER2* in breast cancer cells [@bib0039]. Moreover, PHF8 plays a critical role in sustaining the levels of H3K4me3 in diverse cell types \[[@bib0020],[@bib0040]\]. ChIP experiments reinforced this role of PHF8. Thus, *PHF8* knockdown reduced H3K4me3 levels at *HER2* promoters in the three cell lines tested ([Fig. 2](#fig0002){ref-type="fig"}C). These data support the conclusion that PHF8 participated in the transcriptional regulation of *HER2* by sustaining H3K4 me3 levels. Moreover, H3K27ac, a general activation marker, was downregulated on *HER2* promoter regions in *PHF8* knockdown cells ([Fig. 2](#fig0002){ref-type="fig"}C). Thus, PHF8 may demethylate H3K27 to prime the acetylation of, or indirectly regulate, H3K27ac through its acetyltransferase. Together, our data reveal the role of PHF8 in the transcriptional regulation of *HER2*, in which the underlying mechanisms may involve direct and indirect regulation of multiple factors.

3.3. PHF8 functions as a dominant coactivator downstream in the HER2 signalling pathway {#sec0019}
---------------------------------------------------------------------------------------

Although PHF8 directly participates in the transcriptional regulation of *HER2, PHF8* knockdown reduced *HER2* mRNA levels by approximately 30% ([Fig. 2](#fig0002){ref-type="fig"}B). Thus, we aimed to further identify the genome-wide effects of PHF8 on HER2-regulated genes. MCF10A cells are extensively used to study HER2 function [@bib0041], [@bib0042], [@bib0043]. Thus, we established MCF10A cells that stably expressed HER2 and under doxycycline-inducible *PHF8* shRNAs. HER2 can induce genomic instability [@bib0044], therefore, we used early-passage cell lines to maintain their isogenic status. Consistent with previous reports \[[@bib0042],[@bib0045]\], HER2 overexpression induced proliferation, AKT phosphorylation (p-AKT), and expression of EMT markers (N-cadherin \[CDH2\] and zinc finger E-box binding homeobox 1 \[ZEB1\]) ([Fig. 3](#fig0003){ref-type="fig"}A and B). Notably, silencing *PHF8* attenuated these effects ([Fig. 3](#fig0003){ref-type="fig"}A and B). Moreover, *PHF8* knockdown downregulated overexpressed HER2, indicating that PHF8 may indirectly regulate HER2.Fig. 3PHF8 facilitates HER2 signalling through its tumour-promoter activity. **a.** The proliferation of MCF10A cells overexpressing HER2, with *PHF8* knockdown, or both was assessed using the MTT assay. Data are presented as mean ± SD of three independent experiments. \*\**p* ≤ 0.01. **b.** Western blotting analysis of the expression of HER2, PHF8, and other indicated proteins shown in panel **a** in MCF10A cells. The data represent three independent experiments. A and B, Mock: overexpression control; HER2: HER2 overexpression; shNC: scrambled shRNA; shPHF8: PHF8 shRNAs. **c.** PHF8 knockdown counteracted the activity of most pathways induced by HER2 overexpression. Gene set Enrichment Analysis (GSEA) of Hallmark pathways in HER2-overexpressing cells vs. control cells compared with HER2-overexpressing cells vs. PHF8 knocking down. The *p* values are coloured; normalised enrichment scores (NES) are shown on the x-axis. **d**. Heat map of RNA sequencing Z-score results of 298 PHF8 differentially regulated genes (DRG) that were significantly regulated by HER2 overexpression. **e**. Heat map of the Z-scores of 60 PHF8-associated DRGs contributing most to enriched pathways. **f.** Protein--protein association networks of 60 PHF8-associated DRGs were analysed using STRING. Edges represent protein-protein associations such as direct interactions, gene neighbourhood, co-expression, and co-occurrence.Fig. 3

We next used RNA-seq to analyse cell lines expressing mock/control shRNA, HER2/control shRNA, and HER2/PHF8shRNAs 1 and 2. We identified 838 upregulated and 536 downregulated genes in cells overexpressing HER2 (cut-off of actual fold change = 1.5 \[FC ≥1.5 or ≤ −1.5\] and adjusted *p* value \< 0.05) (Supplementary Table 2). Gene Set Enrichment Analysis (GSEA) [@bib0046] of hallmark gene sets revealed that HER2-regulated genes were significantly enriched in 18 pathways such as TNFα signalling, the EMT transition, the inflammatory response, and mTOR signalling ([Fig. 3](#fig0003){ref-type="fig"}C and Supplementary Table 5), consistent with previous reports using similar parameters [@bib0047], [@bib0048], [@bib0049]. *PHF8* knockdown attenuated most of the pathways induced by HER2 overexpression ([Fig. 3](#fig0003){ref-type="fig"}C and Supplementary Table 6). Importantly, the pathways of E2F targets, mTOR signalling, and interferon responses elevated by HER2 overexpression were significantly counteracted by *PHF8* loss of function ([Fig. 3](#fig0003){ref-type="fig"}C). These data strongly suggest that the general coactivator functions of PHF8 were associated with an HER2-induced transcriptome.

We next defined 298 genes that were differentially regulated (DRGs) by PHF8 by subtraction from HER2-regulated genes using the criteria as follows: same trend of regulation by two *PHF8* shRNAs, where at least one shRNA accounted for \>30% of DRGs, and *p* ≤ 0.05. The 30% cut-off was selected according to the published data for the general regulatory function of PHF8 \[[@bib0020],[@bib0021],[@bib0027]\]. These 298 DRGs clustered into a coactivator (*PHF8* knockdown attenuated the expression of genes upregulated by HER2 or enhanced the expression of genes downregulated by HER2) or a corepressor (*PHF8* knockdown counteracted the expression of genes downregulated by HER2 or enhanced the expression of genes upregulated by HER2) groups ([Figs. 3](#fig0003){ref-type="fig"}D, Supplementary Table 3, and 4). These analyses led us to the general conclusion as follows: The transcriptional coactivator function of PHF8 was dominant compared to its corepressor function. GO biological processes indicate that PHF8 coactivator genes (upregulated by HER2) were enriched in cell proliferation and cytokine production, whereas PHF8 corepressor genes (downregulated by HER2) were enriched in axon and neuron regeneration (Supplementary Figure 5).

To further investigate the biological effects of PHF8 on HER2-regulated genes, we identified genes that contributed to significantly enriched pathways regulated by HER2 overexpression or *PHF8* knockdown from the 298. The result was a 60-gene signature ([Figs. 3](#fig0003){ref-type="fig"}E and Supplementary Table 7). The identification of these genes further demonstrated the dominant coactivator functions of PHF8 downstream of HER2 signalling. Analysis of protein--protein association networks of these 60 genes using STRING [@bib0050] revealed that interleukin-6 (IL-6) is a hub ([Fig. 3](#fig0003){ref-type="fig"}F) that contributes to nine pathways, including the interferon response, TNFa signalling, the EMT, and inflammation (Supplementary Table 7). These data suggest that PHF8 contributed to the tumourigenic functions of HER2 through IL-6.

3.4. PHF8 promotes resistance to the anti-HER2 effects of breast cancer cells through IL-6 {#sec0020}
------------------------------------------------------------------------------------------

We next investigated the regulation of IL-6 by PHF8 and its contribution to HER2 signalling and the resistance of breast cancers to anti-HER2 drugs. Our rationale was as follows: the regulation of IL-6 by HER2 overexpression that ranked higher (Supplementary Table 7), the central position of IL-6 in the protein--protein association network of PHF8-associated DRGs in the context of HER2 ([Fig. 3](#fig0003){ref-type="fig"}F), and the functional importance of IL-6 in HER2 signalling [@bib0051] and in drug resistance \[[@bib0052],[@bib0053]\] especially the resistance to trastuzumab \[[@bib0051],[@bib0054],[@bib0055]\] and lapatinib [@bib0056]. First, we confirmed the regulation of IL-6 by HER2 and PHF8 in MCF10A cell lines ([Fig. 4](#fig0004){ref-type="fig"}A) and in HCC1954 and BT474 lapatinib-resistant (-R) cells [@bib0057] cells ([Fig. 4](#fig0004){ref-type="fig"}B), which possess higher *IL-6* mRNA and protein levels compared with the other cell lines tested (Supplementary Figure 6). We next analysed a human cytokine antibody array and obtained similar results. PHF8 knockdown attenuated the upregulation of IL-6 by HER2 overexpression in MCF10A cells ([Fig. 4](#fig0004){ref-type="fig"}C) and downregulated IL-6 expression in HCC1954 cells ([Fig. 4](#fig0004){ref-type="fig"}D). The regulation of IL-6 by PHF8 in HCC1954 cells was further validated using an ELISA assay ([Fig. 4](#fig0004){ref-type="fig"}E). Notably, angiogenin (ANG) and CCL20 were regulated by HER2 and PHF8 in a pattern similar to that of IL-6 ([Fig. 4](#fig0004){ref-type="fig"}C). However, similar data for PHF8 were not acquired using HCC1954 cells ([Fig. 4](#fig0004){ref-type="fig"}D).Fig. 4PHF8 promotes resistance to anti-HER2 therapies in breast cancer cells through IL-6.**a** and **b.** RT-qPCR analysis of *IL-6* expression. *RPL13A* mRNA served as the control. **c** and **d.** Human Cytokine Antibody Array blots probed with the media from the indicated cells. Western blotting was performed in duplicate, an ELISA was used to measure expression, and the regulated cytokines are marked. **e**. An ELISA was used to measure IL-6 secreted from HCC1954 cells with or without PHF8 knockdown; \* *p* ≤ 0.05, \*\* *p* ≤ 0.01. **f.** MTT analysis of the viability of HCC1954 cells with or without PHF8 knockdown in the presence or absence of IL-6. Cells were treated doxycycline for 72 h and then reseeded into the wells of 96-well plates. IL-6 (100 ng/mL) was added to the cells 24 h before the addition of T-DM1 (48 h) (*n* = 5). **g.** Western blotting analysis of the levels of HER2, PHF8, PARP/c-PARP (cleaved PARP), and STAT3/PSTAT3 in HCC1954 cells treated as in **f**, γ-Tubulin served as the loading control. The data represents three independent experiments.Fig. 4

HCC1954 cells are resistant to trastuzumab [@bib0058] and express PHF8 (Supplementary Figure 7). Therefore, we investigated whether PHF8 and the PHF8-IL-6 axis contributed to such resistance. The IC~50~ of trastuzumab (T-DM1) of HCC1954 cells transfected with a control shRNA was 92.44 ng/ml ([Fig. 4](#fig0004){ref-type="fig"}F). Knockdown of PHF8 expression by the two shRNAs reduced the IC~50~ values to 33.72 ng/ml and 29.68 ng/ml ([Fig. 4](#fig0004){ref-type="fig"}F), suggesting a positive role for PHF8 in the resistance of HCC1954 cells to trastuzumab. When exposed to IL-6 ([Fig. 4](#fig0004){ref-type="fig"}F), inhibition of viability of the HCC1954 cells infected with control shRNA stayed static with increasing T-DM1 concentrations (IC~50~ value = 106.43 ng/ml) ([Fig. 4](#fig0004){ref-type="fig"}F). However, exposure of IL-6 increased the IC~50~ to 104.57 ng/ml and 64.47 ng/ml, in two PHF8-knockdown cell lines, supporting the conclusion that the PHF8-IL6 axis contributed to the resistance of HCC1954 cells to trastuzumab.

[Fig. 4](#fig0004){ref-type="fig"}G illustrates the results of the western blotting analysis of these cells in the presence and absence of T-DM1 (2 ng/ml). PHF8 knockdown slightly reduced the levels of activated STAT3 (p-STAT3), and the addition of IL-6 restored p-STAT3 levels ([Fig. 4](#fig0004){ref-type="fig"}G), supporting the role of PHF8 in regulating IL-6 signalling. T-DM1 treatment of the control cells significantly reduced p-STAT3 levels and induced apoptosis, reflected by the detection of cleaved PARP (c-PARP) ([Fig. 4](#fig0004){ref-type="fig"}G). PHF8 knockdown increased T-DM1-induced apoptosis, and the addition of IL-6 counteracted the induction of apoptosis ([Fig. 4](#fig0004){ref-type="fig"}G), supporting the contribution of the PHF8-IL-6 axis to the resistance of HCC1954 cells to trastuzumab. Experiments with the same setup of lapatinib plus trastuzumab treatment were performed in HCC1954 cells (Supplementary Figure 8a). The results are of the same trend; however, apoptosis cannot be detected obviously since HCC1954 is highly resistant to drugs. Moreover, overexpressing PHF8 in drug-sensitive parental SKBR3 cells showed PHF8 gain-of-function contributes to lapatinib plus trastuzumab resistance of these cells (Supplementary Figure 8b).

3.5. *Phf8* contributes to *HER2*-driven breast tumour development *in vivo* {#sec0021}
----------------------------------------------------------------------------

PHF8 is required for the anchorage-independent growth of HER2+ breast cancer cells [@bib0015]. Our current data support synergism between PHF8 and HER2. Thus, we sought to further study the role of PHF8 in HER2-driven tumour development *in vivo*: For this purpose, we used a *Phf8* knockout mouse model (illustrated in [Fig. 5](#fig0005){ref-type="fig"}A) in which *Her2* was overexpressed under the control of the mouse mammary tumour virus (*MMTV*) long terminal repeat. WT mice (*n* = 42) and *Phf8* KO mice (*n* = 44) with an *MMTV-Her2* background were genotyped (tail) ([Fig. 5](#fig0005){ref-type="fig"}B), and PHF8 levels of tumour samples were determined using western blotting ([Fig. 5](#fig0005){ref-type="fig"}C). There was no significant difference between the numbers and time to detection of mammary tumours that developed in the WT and *Phf8* KO mice (185.8 ± 42.8 \[mean ± SD\] and 180 ± 39.2 days, respectively) ([Fig. 5](#fig0005){ref-type="fig"}D). However, the average weight (2.64 ± 1.26 g) of tumours of *Phf8* KO mice was significantly lower compared with that of the WT mice (3.22 ± 1.40 g) ([Fig. 5](#fig0005){ref-type="fig"}E). Moreover, the ratio of the relative tumour weight as a percentage of total body weight of *Phf8* KO mice was significantly reduced (6.97% ± 3.17% from 9.31% ± 1.26% for WT mice) ([Fig. 5](#fig0005){ref-type="fig"}F). These data indicate that PHF8 played critical roles in tumour growth rather than in tumour initiation. This conclusion is further supported by the significantly reduced proliferative index of *Phf8* KO mice (*n* = 7) compared to that of WT mice (*n* = 6) (12.47% ± 4.56% vs. 3.57% ± 2.18%; *p* = 0.002).Fig. 5Functional impact of PHF8 on HER2-induced tumourigeneses and inflammatory response in vivo. **a.**Schematic of floxed *Phf8* and the corresponding amino acid sequence. **b**. Genotyping of *Her2, flox,* and *Cre* using tail DNA from the indicated mouse. kbp: Kilobase pair. **c.** Western blotting analysis of PHF8 and HER2 levels of mice with the indicated genotypes. **d--f**. Tumour onset date (**d**), tumour weight (**e**), and tumour ratio (**f**) of WT to *Phf8* KO mice. Each point represents an individual animal. The Student *t*-test was used to calculate the significance of differences between the KO and WT groups (*n* = 86). **g.** IHC analysis of PHF8, Ki67, CD4, and CD8 levels in tumour tissues from *Phf8* KO and WT mice (magnification, 200 ×, bar = 10 μm. **h**. Comparison of infiltrating T cells in tumours from WT and *Phf8* KO mice. The percentages of intraepithelial and stromal tumour-infiltrating CD8+ and CD4+ *T* cells were quantified in 200x fields. **I**. Western blotting analysis of HER2 and PHF8 levels in primary tumour cell lines from *Phf8* KO and WT mice. **J**. RT-qPCR mRNA levels of *Il-6* in primary tumour cell lines. Il-6 expression was normalised by both *Rpl13a* and *β-actin*. \* *p* ≤ 0.05.Fig. 5

PHF8 contributes to the regulation of IL-6 and the IL-6-immune response network associated with tumour growth [@bib0059], [@bib0060], [@bib0061]. Therefore, we next analysed infiltrating T cells. Compared with widespread T cells in WT mice (*n* ≥ 7), the tumours from *Phf8* KO mice (*n* ≥ 5) had few intratumoural T cells and few T cells peripheral to the tumour mass and in collagen bundles ([Fig. 5](#fig0005){ref-type="fig"}G). Analysis of CD4 and CD8 expression revealed a significant reduction of intratumoural and peritumoural infiltrating T cells in *Phf8* KO mice compared with those in WT mice ([Fig. 5](#fig0005){ref-type="fig"}H). These data are consistent with those of studies indicating that in the tumour microenvironment, IL-6 promotes inflammation-induced CD8+ *T* cell trafficking in tumours [@bib0062] and in stromal cells such as CD4+ regulatory T cells (Treg) that support tumourigenesis. Next, we asked whether the regulation of IL-6 by PHF8 is conserved. For this purpose, we established 13 WT and 9 KO primary cultures from WT (*n* = 8) and KO (*n* = 6) mice, respectively. HER2 and PHF8 levels were determined using western blotting ([Fig. 5](#fig0005){ref-type="fig"}I). Importantly, the *Il-6* mRNA levels in cells of KO mice were significantly lower than those of WT mice ([Fig. 5](#fig0005){ref-type="fig"}J), consistent with the cell line data. Together, these data indicate that the PHF8-IL-6 axis mediated T cell infiltration in HER2-driven tumour development.

4. Discussion {#sec0022}
=============

The resistance to anti-HER2 drugs, such as to lapatinib or trastuzumab, remains a hurdle to achieving successful therapy of HER2+ breast cancers [@bib0002]. Thus, it is critically important to identify novel therapeutic targets. Specific inhibitors of epigenetic factors may serve this purpose. Here, we used *in vitro* and *in vivo* approaches to demonstrate synergy between the histone demethylase PHF8 and HER2 and the oncogenic functions of PHF8 in HER2-driven tumour development. Our data have significant therapeutic implications for targeting PHF8 in HER2+ breast cancers.

The oncogenic functions of PHF8 contribute to diverse cancers [@bib0022], [@bib0023], [@bib0024], [@bib0025], [@bib0026]. We [@bib0015] and Wang et al. [@bib0027] discovered such functions of PHF8 in several subtypes of breast cancers that are associated with a significant increase of *PHF8* mRNA levels. However, our previous [@bib0015] and current approaches using an updated dataset that includes more samples [@bib0029] normal and 1085 breast cancer tissues did not demonstrate significant upregulation of *PHF8* mRNA levels in HER2+ breast cancers. By contrast, our IHC analysis presented here from a pool of \>500 samples revealed a significant increase in PHF8 levels in all subtypes of breast cancers. Although the mRNA data do not agree with those acquired using breast cancer arrays, the discrepant mRNA and protein levels of *PHF8* in breast cancers indicate the roles of the post-transcriptional [@bib0015] and post-translational [@bib0027] regulation of PHF8 expression. Although our previous study [@bib0015] demonstrated the transcriptional regulation of *PHF8* by ectopically expressed HER2, the MYC-miR-22-PHF8 regulatory axis may contribute to the regulation of PHF8 by HER2 signalling for the following reasons: 1) MYC is a key player in HER2-mediated oncogenesis \[[@bib0063],[@bib0064]\]; 2) The expression of miR-22 expression is lower in HER2+ breast cancers [@bib0065]; 3) miR-22 downregulates PHF8 levels in SKBR3 cells [@bib0015]. Moreover, LET-7 targets PHF8, which implicates LET-7 as a component of a putative HER2--LET-7--PHF8 axis for the following reasons: 1) LET-7 levels are lower in HER2+ breast cancers [@bib0065]; 2) HER2 represses LET-7 expression through ERK signalling [@bib0066] by activating LIN28, which inhibits the synthesis of LET-7 family members [@bib0067]; 3) HER2 inhibits LET-7 through a pathway involving AKT-MYC [@bib0068]. Together, these findings indicate that HER2 regulates PHF8 through multiple mechanisms. Further studies are required to prove the existence of an HER2-microRNAs--PHF8 axis.

RNA-seq and pathway analyses reported here indicate that the transcriptional coactivator role of PHF8 downstream of HER2 signalling is dominant over its corepressor role, consistent with the results of other studies \[[@bib0015],[@bib0020],[@bib0021],[@bib0027]\]. *HER2* is expressed at a higher rate as a function of its copy number in *HER2*-amplified breast cancer cells \[[@bib0039],[@bib0069],[@bib0070]\]. Thus, including PHF8 as a component of the MLL complex that influences the activity of H3K9 acetyltransferase [@bib0039] helps to decipher the epigenetic regulatory machinery of *HER2*. We reasoned, therefore, that constitutive transcription of *HER2* may lower H3K9me2 levels, and it is possible that PHF8 plays a role of sustaining the low occupancy of H3K9me2 in the HER2 genomic region. Further, *HER2* is transcriptionally upregulated by tamoxifen, an ER antagonist, in ER+ breast cancers and by radiation therapy of triple-negative breast cancers [@bib0004], [@bib0005], [@bib0006]. Thus, HER2 signalling contributes to resistance to endocrine treatment or radiotherapy, and PHF8 may serve as a transcriptional coactivator in breast cancer cells with *HER2* amplification that overexpresses HER2.

HER2 signalling-specific DRGs regulated by PHF8 were enriched in the GO category "positive regulation of cell proliferation" followed by chemokine/cytokine biosynthetic pathways, implicating PHF8 in the immune response to tumours and its established functions in the regulation of the cell cycle. IL-6, CD74, TGFB2, WNT5A, and HMOX1 represent major components for cytokine-associated pathways.

IL-6 signalling is considered a "malevolent player" in tumour progression [@bib0059]. Analysis on IL-6 levels in subgroups of HER2/PHF8 using TCGA breast cancer data revealed no significant correlation between HER2/PHF8 and IL6 mRNA levels (data not shown). It is possibly due to two reasons: First, PHF8 is heavily subject to post-transcriptional and post-translational regulations, therefore, its mRNA levels may not truthfully reflect its actual protein levels; Secondly, tumour tissue from patients include immune, neutrophils and stromal cells from which IL-6 is mainly produced \[[@bib0059],[@bib0071]\]. Importantly, our data using primary tumour cell lines from the mouse model are consistent with our data from the cell lines ([Fig. 5](#fig0005){ref-type="fig"}j). Notably, IL-6 has significant tumour-inhibitory effects, because it influences tissue recruitment of T cells [@bib0072] and serves as a key player in the activation, proliferation, and survival of lymphocytes during immune responses that promote antitumour adaptive immunity [@bib0059]. Thus, our IHC data on CD4 and CD8 expressions on tumour tissues for the infiltration T cells can indirectly interpret the consequence of Il-6 secretion by tumour cells.

TGF-β and WNT signalling pathways play key roles in the EMT and in the acquisition of the metastatic potential of cancer stem cells and their resistance to therapy, and they are immunosuppressive [@bib0073]. The coactivator functions of PHF8 that influence the expression of cytokines may lead to opposing outcomes. However, the reduction of infiltrating T cells in the tumours of *Phf8* KO mice demonstrates a positive role for PHF8 in the infiltration of T cells into a tumour. Thus, PHF8 may play an important role in the immune response by altering the tumour microenvironment and influencing T cell trafficking to tumour sites by regulating cytokine production.

In addition to its dominant coactivator function, PHF8 acts as a corepressor [@bib0074]. Specifically, PHF8 is phosphorylated by ERK2 upon IFNꝩ treatment and dissociates from repressive promoters where PHF8 forms a complex with HDAC1 and SIN3A in the static state [@bib0074]. This mechanism may apply to the HER2 function, because ERK can be activated by HER2 signalling \[[@bib0002],[@bib0003]\]. Genome-wide PHF8 ChIP-seq in the MCF10A cell system is sought to decipher how PHF8 plays its corepressor function on the genes identified in this study. Genome-wide PHF8 ChIP-seq analyses of MCF10A cells may help decipher the mechanism through which PHF8 acts as a corepressor to regulate the genes identified here.
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